Necrotizing Enterocolitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Necrotizing Enterocolitis – Drugs In Development, 2024 report and make more profitable business decisions.
Necrotizing Enterocolitis is the most common type of infection seen in neonates where inflammation of the intestine leads to mucosal damage causing necrosis or death of cells and tissues. Most observed in premature neonates or in infants weighing less than 1500g leading the mortality rate to greater than 50 percent. Genetic mutations also play a role in this condition. Bacterial invasion into the intestinal wall is the major cause of this condition. It could lead to sepsis and ultimately death. Signs and symptoms are variable and non-specific but most commonly fatigueness, dullness or decreased activity, vomiting, and blood in stool are the common symptoms observed. Diagnosis is an abdominal examination, CBP count, stool examination to find out the pathogens, breath hydrogen test and other radiographic findings. Initial course of management is NPO (nothing by mouth), airway, breathing and circulation support in extreme conditions, antibiotics, IV fluids. Surgical intervention in complicated cases.
The Necrotizing Enterocolitis drugs in development market research report provide comprehensive information on the therapeutics under development for Necrotizing Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Necrotizing Enterocolitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Necrotizing Enterocolitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 12 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Necrotizing Enterocolitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Necrotizing Enterocolitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Necrotizing Enterocolitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Avexegen Therapeutics IncBoobyBiome Ltd
Glycohub Inc
Glycosyn LLC
Infant Bacterial Therapeutics AB
Leadiant Biosciences Inc
Liminal BioSciences Inc
Noveome Biotherapeutics Inc
Plakous Therapeutics Inc
Scioto Biosciences Inc
Siolta Therapeutics Inc
University of Pittsburgh
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Necrotizing Enterocolitis reports